A comparative study of 500 mg BID and 250 mg BID of prophylactic oral ganciclovir in post–kidney transplant “CMV at risk” recipients
- 1 February 1999
- journal article
- clinical trial
- Published by Elsevier in Transplantation Proceedings
- Vol. 31 (1-2) , 1125-1126
- https://doi.org/10.1016/s0041-1345(98)01930-7
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Oral Ganciclovir in the Prevention of Cytomegalovirus Infection in Postkidney Transplant “CMV at Risk” Recipients: A Controlled, Comparative Study of Two Regimens (750 mg Bid and 500 mg Bid)Transplantation Proceedings, 1998
- Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post‐kidney transplant patients*Clinical Transplantation, 1997
- GanciclovirNew England Journal of Medicine, 1996
- Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus— and cytomegalovirus-seropositive patientsClinical Therapeutics, 1995
- INCIDENCE OF CYTOMEGALOVIRUS DISEASE IN CYCLOSPORINE-TREATED RENAL TRANSPLANT RECIPIENTS BASED ON DONOR/RECIPIENT PRETRANSPLANT IMMUNITYTransplantation, 1987
- EFFECT OF TREATMENT WITH CYCLOSPORINE VERSUS AZATHIOPRINE ON INCIDENCE AND SEVERITY OF CYTOMEGALOVIRUS INFECTION POSTTRANSPLANTATIONTransplantation, 1985